ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (963)	2/1/2000 10:58:00 PM
From: SnowShredder	of 4474

Here are some of my notes..(disclaimer...do you own DD, as my notes may not be 100% accurate as they may have been taken 1/2 awake due to early mornings/late nights, skiing in the afternoons, with the poster sessions in the evening : ) about one of their posters @ Keystone, Effcient Killing of Primary Human T Lymphocytes engineered with a humanized FAS Receptor-Based suicide switch...it was by Daniel Thomis et al. and Clackson was last author...It involved transducing donor T cells ex vivo with a retroviral vector containing Fas to treat GvHD. The system involved AP1903/Fas. They had very specific induced expression. If GvHD occurs they would give patient the drug and the infused T-cells would then die. About 80% die after the first dose and 40% survive from the remaining 20% after the next does. In patients the dose might be every 2 days via IV drip. This was done in vitro...and they did not have an in vivo model. Best of Luck, Where'd He Go? FWIW...Scott, I took you off I...water under the bridge : )

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next